<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04542759</url>
  </required_header>
  <id_info>
    <org_study_id>CI-004-215</org_study_id>
    <nct_id>NCT04542759</nct_id>
  </id_info>
  <brief_title>Effect of Topical Besifloxacin on Ocular Surface Bacterial Microbiota Prior to Cataract Surgery</brief_title>
  <official_title>Effect of Topical Besifloxacin on Ocular Surface Bacterial Microbiota Prior to Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Oftalmología Fundación Conde de Valenciana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto de Oftalmología Fundación Conde de Valenciana</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Describe the efficacy of the use of topical besifloxacin in reducing the conjunctival&#xD;
      microbiota as a prophylactic measure in patients scheduled for cataract surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized double-blind clinical trial. Study carried out in a single center between January&#xD;
      and April 2017. 60 eyes were included that were randomly divided in a 1: 1 ratio into two&#xD;
      groups. The first group received placebo (hydroxypropylmethylcellulose drops) while the&#xD;
      second group received 0.6% besifloxacin drops four times a day for 3 days. All of them had a&#xD;
      conjunctival cul-de-sac culture before and after treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of positive cultures before and after treatment in each arm</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>A conjunctival cul-de-sac sample will be taken before starting treatment and before surgery, which will be cultured on 3 different media types: Blood, Chocolate and Sabouraud agar.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Microbial Disease</condition>
  <condition>Cataract Senile</condition>
  <arm_group>
    <arm_group_label>Besifloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 DROP 4 TIMES A DAY FOR 3 DAYS PRIOR SURGERY</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydroxypropyl methylcellulose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 DROP 4 TIMES A DAY FOR 3 DAYS PRIOR SURGERY</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Besifloxacin Ophthalmic</intervention_name>
    <description>Prophylaxis for endophthalmitis</description>
    <arm_group_label>Besifloxacin</arm_group_label>
    <other_name>Besivance ophthalmic suspension 0.6%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxypropyl Methylcellulose Ophthalmic Ophthalmic Solution</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Hydroxypropyl methylcellulose</arm_group_label>
    <other_name>Artelac eye drops</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects over 18 years of age scheduled for cataract surgery in the established study&#xD;
             period.&#xD;
&#xD;
          -  Subjects physically and mentally capable of applying the eye drops or having a person&#xD;
             available to help in the correct administration of the eye drops 4 times a day.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - Active eye infection (bacterial, viral, fungal or parasitic) such as blepharitis and&#xD;
             / or conjunctivitis.&#xD;
&#xD;
          -  Known allergy or any contraindication to the use of quinolones or any of the&#xD;
             components of the drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eduardo Chavez-Mondragon, MD</last_name>
    <role>Study Director</role>
    <affiliation>Instutute of Ophthalmology &quot;Conde de Valenciana&quot;</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Ophthalmology, Conde de Valenciana Foundation</name>
      <address>
        <city>Mexico, City</city>
        <state>Mexico City</state>
        <zip>06800</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 19, 2020</study_first_submitted>
  <study_first_submitted_qc>September 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2020</study_first_posted>
  <last_update_submitted>September 2, 2020</last_update_submitted>
  <last_update_submitted_qc>September 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Besifloxacin</keyword>
  <keyword>prophylaxis</keyword>
  <keyword>cataract surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Besifloxacin</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

